TSHA-102 explained

TSHA-102 is an experimental gene therapy developed by Taysha Gene Therapies for Rett syndrome, delivered via adeno-associated virus serotype 9.[1] [2] [3] [4] [5]

Notes and References

  1. Philippidis . Alex . StockWatch: Astellas Hones Gene Therapy Focus with Taysha Stake: Tricida shares crater after failed Phase III trial; Vaxcyte bolsters challenge to Pfizer with clinical success; ESSA triples after acing prostate cancer study . GEN Edge . 1 January 2022 . 4 . 1 . 809–815 . 10.1089/genedge.4.1.137. 253331384 .
  2. Philippidis . Alex . StockWatch: Seven Analysts Cut Price Target for Taysha on FDA Advice, Job Cuts: Gene therapy developer says call for randomized placebo-controlled trial is 'unfeasible'; Evelo falls on clinical miss; HillStream jumps on Dana-Farber deal . GEN Edge . 1 January 2023 . 5 . 1 . 128–132 . 10.1089/genedge.5.1.28. 257006849 .
  3. Philippidis . Alex . Sarepta Duchenne Muscular Dystrophy Candidate Faces U.S. Food and Drug Administration Assay Request, Patent Suit . Human Gene Therapy . 1 October 2020 . 31 . 19–20 . 1031–1033 . 10.1089/hum.2020.29137.bfs. 33074027 . 224780854 .
  4. Philippidis . Alex . Taysha Faces Stock Delisting, Scraps $75M Durham Manufacturing Facility: Company aims to preserve capital while anticipating second-half clinical milestones for key programs, with Q1 results expected Thursday . GEN Edge . 1 January 2023 . 5 . 1 . 362–367 . 10.1089/genedge.5.1.70. 258737047 .
  5. Philippidis . Alex . StockWatch: Illumina Results Leave Investors, Analysts Anxious: Taysha zooms on $150M PIPE financing; Alaunos plunges on job cuts; Design nosedives on patient 'reactions'; Phase IIb trial failure sinks Galecto; Zynerba quadruples on up-to-$200M buyout by Harmony . GEN Edge . 1 January 2023 . 5 . 1 . 549–556 . 10.1089/genedge.5.1.106. 265960414 .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "TSHA-102".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.